This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2009-0132v1 14/12/1209    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Brandt, A. Articles by Hemminki, K. PubMed PubMed Citation Articles by Brandt, A. Articles by Hemminki, K.

Epidemiology and Community Health

Age at Diagnosis and Age at Death in Familial Prostate Cancer

^aDivision of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany; ^bInstitute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg, Germany; ^cCenter for Primary Care Research, Lund University, Malmö, Sweden; ^dStanford Prevention Research Center, Stanford University School of Medicine, Stanford, California, USA; ^eCenter for Family and Community Medicine, Karolinska Institute, Huddinge, Sweden

Key Words. Prostate cancer • Familial prostate cancer • Age of diagnosis • Cumulative risk

Correspondence: Andreas Brandt, Dipl. Math., Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany.Telephone: 49-6221-421805;Fax: 49-6221-421810;e-mail: andreas.brandt{at}dkfz.de

Received June 30, 2009; accepted for publication November 5, 2009; first published online in THE ONCOLOGIST Express on November 25, 2009.

Disclosures

Andreas Brandt: None; Justo Lorenzo Bermejo: None; Jan Sundquist: None; Kari Hemminki: None.

Section editor Derek Raghavan has disclosed no financial relationships relevant to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

Objectives. A family history of prostate cancer is associated with a higher risk for prostate cancer to first-degree relatives. If greater surveillance of men at familial risk is considered to be useful, population-based estimates of the differences in the age at diagnosis between familial and sporadic prostate cancer cases are needed.

Methods. The men in the nationwide Swedish Family-Cancer Database were classified according to the number and type of affected first-degree relatives (father or brother) and according to the relative's age at diagnosis. The cumulative incidence of prostate cancer and cumulative prostate cancer–specific mortality were estimated using a stratified Cox model.

Results. The cumulative incidence was highest for men with multiple affected first-degree relatives, and it was higher for brothers than for sons of prostate cancer patients. The age to reach the same cumulative incidence as the general population at age 55 years decreased with decreasing age at diagnosis of the relative, ranging from 48.7 years (father diagnosed before 60 years of age) to 53.7 years (father diagnosed after 82 years of age). Prostate cancer–specific mortality was also related to the number and type of affected relatives but there was no clear evidence for a dependency on the age at diagnosis of the relative.

Conclusions. Men with a father or a brother affected by prostate cancer are diagnosed and die at earlier ages than men without a family history of prostate cancer. This study should encourage further analysis in order to assess the risks and benefits of screening for prostate cancer in men at higher risk.